Generation Bio Co (GBIO)

Etorro trading 970x250
Generation Bio Co (GBIO) Logo

About Generation Bio Co

Generation Bio Co., a genetic medicines company, develops gene therapies for the treatment of rare and prevalent diseases. The company is developing a portfolio of programs for rare and prevalent diseases of the liver and retina. It also focuses on the diseases of skeletal muscle, central nervous system, and oncology. The company was formerly known as Torus Therapeutics, Inc. and changed its name to Generation Bio Co. in November 2017. Generation Bio Co. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts. Address: 301 Binney Street, Cambridge, MA, United States, 02142

Generation Bio Co News and around…

Latest news about Generation Bio Co (GBIO) common stock and company :

12 Health Care Stocks Moving In Monday's After-Market Session
24 Jan, 2022 FinancialContent

Gainers Aptorum Group (NASDAQ:APM) stock moved upwards by 17.3% to $1.9 during Monday's after-market session. This security traded at ...

12 Health Care Stocks Moving In Friday's After-Market Session
14 Jan, 2022 FinancialContent

Gainers Avinger (NASDAQ:AVGR) stock moved upwards by 9.7% to $0.34 during Friday's after-market session. This security traded at a ...

Generation Bio to Present at 40th Annual J.P. Morgan Healthcare Conference
05 Jan, 2022 Yahoo! Finance

CAMBRIDGE, Mass., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announced today that the company will present at the virtual 40th Annual J.P. Morgan Healthcare Conference on Wednesday, Jan. 12, 2022. Presentation DetailsDate: Wednesday, Jan. 12, 2022Time: 8:15-8:55 a.m. ET A live webcast of the company presentation and Q&A session will be available on the investor secti

SHAREHOLDER ALERT: Robbins LLP Investigates Generation Bio Co. (GBIO) on Behalf of Shareholders
29 Dec, 2021 FinancialContent

Generation Bio Co. (GBIO) Reports Poor Results for Preclinical Studies for Hemophilia A Program

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors Generation Bio Co. - GBIO
20 Dec, 2021 Yahoo! Finance

NEW YORK, Dec. 19, 2021 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Generation Bio Co. (“Generation” or the “Company”) (NASDAQ: GBIO). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980. The investigation concerns whether Generation Bio and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining the cl

AWM Investment Company, Inc. Buys Destination XL Group Inc, LiqTech International Inc, Gambling. ...
16 Dec, 2021 Yahoo! Finance

New York, NY, based Investment company AWM Investment Company, Inc. (Current Portfolio) buys Destination XL Group Inc, LiqTech International Inc, Gambling.com Group, PLBY Group Inc, Veru Inc, sells , Generation Bio Co, American Public Education Inc, Ondas Holdings Inc, Medicenna Therapeutics Corp during the 3-months ended 2021Q3, according to the most recent filings of the investment company, AWM Investment Company, Inc..

Generation Bio (NASDAQ:GBIO) Is In A Good Position To Deliver On Growth Plans
16 Dec, 2021 Yahoo! Finance

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

50 Biggest Movers From Yesterday
15 Dec, 2021 FinancialContent

Gainers Sidus Space, Inc. (NASDAQ: SIDU) shares jumped 143.8% to settle at $12.19 on Tuesday after the company priced its IPO at ...

Mid-Afternoon Market Update: Dow Falls 100 Points; Terminix Shares Spike Higher
14 Dec, 2021 FinancialContent

Toward the end of trading Tuesday, the Dow traded down 0.30% to 35,544.59 while the NASDAQ fell 1.53% to 15,176.99. The S&P also ...

12 Health Care Stocks Moving In Tuesday's Intraday Session
14 Dec, 2021 FinancialContent

Gainers Galera Therapeutics (NASDAQ:GRTX) shares increased by 108.0% to $2.87 during Tuesday's regular session. As of 12:30 ...

Generation Bio Hits 52-Week Low After Preclinical Data From Hemophilia A Program
14 Dec, 2021 FinancialContent

Generation Bio Co(NASDAQ: GBIO)provided an updateon factor VIII expression from a series of mouse and companion ...

Mid-Day Market Update: Nasdaq Tumbles 200 Points; MIND Technology Shares Jump
14 Dec, 2021 FinancialContent

Midway through trading Tuesday, the Dow traded down 0.17% to 35,588.72 while the NASDAQ fell 1.3% to 15,213. The S&P also fell, ...

34 Stocks Moving In Tuesday's Mid-Day Session
14 Dec, 2021 FinancialContent

Gainers Exicure, Inc. (NASDAQ: XCUR) rose 41.8% to $0.3830. Exicure’s Audit Committee recently concluded that Grant Corbett ...

Mid-Morning Market Update: Markets Mostly Lower; Producer Prices Rise 0.8% In November
14 Dec, 2021 FinancialContent

Following the market opening Tuesday, the Dow traded up 0.06% to 35,673.60 while the NASDAQ fell 1.08% to 15,247.22. The S&P also ...

12 Health Care Stocks Moving In Tuesday's Pre-Market Session
14 Dec, 2021 FinancialContent

Gainers Galera Therapeutics (NASDAQ:GRTX) stock increased by 134.05% to $3.23 during Tuesday's pre-market session. ...

Generation Bio Provides Update on Preclinical Studies for Hemophilia A Program
14 Dec, 2021 Yahoo! Finance

Innovations in closed-ended DNA (ceDNA) and cell-targeted lipid nanoparticle (ctLNP) production processes generated peak mean of 205% normal human factor VIII expression in miceNon-human primates (NHPs) demonstrated up to 2% normal human factor VIII expression, and higher-than-expected variability within and between studiesCompany is using insights from preclinical studies to advance additional novel proprietary ctLNPs to improve species translation to meet target profile for a development candi

How The Parts Add Up: NIFE Targets $103
06 Dec, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Direxion Fallen Knives ETF ETF (NIFE), we found that the implied analyst target price for the ETF based upon its underlying holdings is $103.41 per unit.

Generation Bio Reports Business Highlights and Third Quarter 2021 Financial Results
10 Nov, 2021 Yahoo! Finance

New preclinical retinal data illustrating potential for expansive therapeutic applications of ctLNP delivery presented at ESGCT 2021 Annual Virtual CongressCAMBRIDGE, Mass., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, reported recent business highlights and third quarter 2021 financial results. “We are building a leading non-viral genetic medicine company with the pot

NIFE's Underlying Holdings Imply 46% Gain Potential
04 Nov, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Direxion Fallen Knives ETF ETF (NIFE), we found that the implied analyst target price for the ETF based upon its underlying holdings is $106.37 per unit.

Oversold Conditions For Generation Bio (GBIO)
27 Oct, 2021 FinancialContent

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100..

Generation Bio Presents Data Demonstrating First Lipid Nanoparticle to Achieve Uniform Retinal Transduction and Tolerability via Sub-Retinal Delivery of ceDNA and mRNA at the European Society of Gene and Cell Therapy 2021 Annual Virtual Congress
22 Oct, 2021 Yahoo! Finance

Sub-retinal delivery of closed-ended DNA (ceDNA) using a retina-specific cell-targeted LNP (ctLNP) demonstrated broad photoreceptor distribution, durable expression and tolerability in rodents; potential to address inherited retinal diseases with full gene replacement Uniform retinal transduction and tolerability also demonstrated for ctLNP delivery of mRNA following sub-retinal injection in non-human primates; potential best-in-class non-viral delivery of mRNA for gene editing in the retina CAM

Generation Bio to Present at Jefferies Virtual Gene Therapy/Editing Summit
21 Oct, 2021 Yahoo! Finance

CAMBRIDGE, Mass., Oct. 21, 2021 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announced today that Geoff McDonough, M.D., president and chief executive officer, will participate in a fireside chat at the Jefferies Virtual Gene Therapy/Editing Summit on Wednesday, October 27 at 5:00 p.m. ET. A live webcast of the panel will be available on the investor section of the company’s website

Generation Bio to Present at European Society of Gene and Cell Therapy 2021 Annual Virtual Congress
15 Oct, 2021 Yahoo! Finance

CAMBRIDGE, Mass., Oct. 15, 2021 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, today announced an oral presentation at the European Society of Gene and Cell Therapy (ESGCT) Annual Virtual Congress taking place October 19-22. The presentation will highlight preclinical advances from the company’s retina therapeutic area. “We are excited to share our preclinical data demonstrating broad

Director Of Generation Bio Makes $2.0M Sale
30 Sep, 2021 Yahoo! Finance

Jason Rhodes, Director at Generation Bio (NASDAQ:GBIO), made a large insider sell on September 29, according to a new SEC filing. What Happened: A Form 4 filing from the U.S. Securities and Exchange Commission on Wednesday showed that Rhodes sold 81,088 shares of Generation Bio at prices ranging from $24.59 to $25.70. The total transaction amounted to $2,059,519. Rhodes still owns a total of 1,167,545 shares of Generation Bio worth, $28,838,361. Generation Bio shares are trading up 1.69% at $24.

Analysts See 53% Upside For The Holdings of NIFE
27 Sep, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Direxion Fallen Knives ETF ETF (NIFE), we found that the implied analyst target price for the ETF based upon its underlying holdings is $111.22 per unit.

48 Biggest Movers From Friday
20 Sep, 2021 FinancialContent

Gainers Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) shares jumped 135.4% to settle at $5.32 on Friday. The stock possibly traded ...

12 Health Care Stocks Moving In Friday's Intraday Session
17 Sep, 2021 FinancialContent

Gainers Corvus Pharmaceuticals (NASDAQ:CRVS) shares rose 78.31% to $4.03 during Friday's regular session. The current volume of ...

Generation Bio Co. (NASDAQ:GBIO) insiders' US$600k purchase saw a boost of US$66k after market cap rose US$93m
17 Sep, 2021 Yahoo! Finance

Generation Bio Co. ( NASDAQ:GBIO ) insiders who bought shares over the past year were rewarded handsomely last week...

60 Biggest Movers From Yesterday
25 Aug, 2021 FinancialContent

Gainers Triple-S Management Corporation (NYSE: GTS) shares surged 45.5% to close at $35.20 on Tuesday. GuideWell Mutual Holding ...

38 Stocks Moving In Tuesday's Mid-Day Session
24 Aug, 2021 FinancialContent

Gainers Triple-S Management Corporation (NYSE: GTS) shares jumped 45.3% to $35.15. GuideWell Mutual Holding Corporation, parent ...

Generation Bio Co (GBIO) is a NASDAQ Common Stock listed in , ,

970x250